Infusion of dendritic cells pulsed with HLA-A2-specific prostate- specific membrane antigen peptides: A phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease

Prostate

Volumn 38, Issue 1, 1999, Pages 73-78

  Murphy, Gerald P ^a   Tjoa, B A ^a   Simmons, S J ^a   Jarisch, J ^a   Bowes, V A ^a   Ragde, H ^a   Rogers, M ^a   Elgamal, A ^a   Kenny, G M ^a   Cobb, O E ^a   Ireton, R C ^a   Troychak, M J ^a   Salgaller, M L ^b   Boynton, A L ^a  

^a NORTHWEST HOSPITAL   (United States)

^b Northwest Biotherapeutics Inc   (United States)

Author keywords

Cancer vaccine; Clinical trial; Dendritic cells (DC); Hormone refractory; Immunotherapy; Metastatic; Prostate cancer; Prostate specific membrane antigen (PSMA)

Indexed keywords

BICALUTAMIDE; CANCER VACCINE; FLUTAMIDE; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 2; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL TRIAL; DENDRITIC CELL; DRUG EFFECT; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BONE NEOPLASMS; CANCER VACCINES; CARBOXYPEPTIDASES; DENDRITIC CELLS; GLUTAMATE CARBOXYPEPTIDASE II; HLA-A2 ANTIGEN; HORMONES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; VACCINES, SYNTHETIC;

EID: 0032892718     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19990101)38:1<73::AID-PROS9>3.0.CO;2-V     Document Type: Article

References (10)

1. Melman I, Turley SJ, Steinman RM. Antigen processing for amateurs and professionals. Trends Cell Biol 1998;8:231-235.
2. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-296.
3. Tjoa B, Erickson S, Barren III R, Ragde H, Kenny G, Boynton A, Murphy G. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate 1995;27:63-39.
4. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy of prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996;29:371-380.
5. Tjoa BA, Erickson SJ, Bowes VA, Ragde H, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Boynton AL, Murphy GP. Follow-up evaluation of prostate cancer patients infused with autolo-gous dendritic cells pulsed with PSMA peptides. Prostate 1997; 32:272-278.
6. Murphy GP, Troychak MJ, Cobb OE, Bowes VA, Kenny RJ, Barren RJ III, Kenny GM, Ragde H, Wolfert RL. Evaluation of PSA, free PSA, PSMA, and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer. Prostate 1997;33:141-146.
7. Tjoa B, Simmons S, Bowes V, Ragde H, Rogers M, Elgamal A, Kenny GM, Cobb OE, Ireton RC, Troychak MJ, Salgaller ML, Boynton AL, Murphy GP. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 1998;36:39-44.
8. Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren III RJ, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL. Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostatic cancer patients. Prostate 1997;33:281-285.
9. Landis S, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998;48:6-29.
10. Jones G, Mettlin C, Murphy G, Guinan P, Herr H, Hussey D, Chmiel J, Fremgen A, Clive R, Zuber-Ocwieja K, Winchester D. Patterns of care for carcinoma of the prostate gland: results of a national survey of 1984 and 1990. J Am Coll Surg 1995;180:545-554.